Abstract
5/2025
vol. 112
Review article
JAK Inhibitors in the Treatment of Psoriasis and Psoriatic Arthritis and the Risk of Skin Malignancies: a Review of Current Evidence
Marta Kacprzyk
1
,
Magdalena Masajada
1, 2
,
Aleksandra Kulbat
3, 4, 5
,
Karolina Richter
3, 6
,
Paweł Brzewski
1, 2
,
Wojciech M. Wysocki
3, 4, 5
- Department of Dermatology and Venereology, Stefan Zeromski Municipal Hospital, Krakow, Poland
- Chair of Dermatology and Venereology, Faculty of Medicine, Andrzej Frycz Modrzewski Krakow University, Krakow, Poland
- Chair of Surgery, Faculty of Medicine, Andrzej Frycz Modrzewski Krakow University, Krakow, Poland
- Department of Oncological Surgery, 5th Military Clinical Hospital, Krakow, Poland
- National Institute of Oncology, Maria Sk³odowska-Curie Memorial, Warsaw, Poland
- Department of General, Oncological, Metabolic and Emergency Surgery, University Hospital, Krakow, Poland
Dermatol Rev/Przegl Dermatol 2025, 112, 306-313
Online publish date: 2025/12/30
Psoriasis and psoriatic arthritis are chronic immune-mediated disorders associated with substantially impaired quality of life and comorbidities. Janus kinase (JAK) inhibitors have recently emerged as highly efficient therapeutic agents for the treatment of various inflammatory and hematologic diseases. Nevertheless, there are some concerns about potentially increased risks of infections and therapy-induced malignancies associated with utilization of JAK inhibitors. In this study, we review the current knowledge about the role of particular components of the JAK/STAT pathway in the carcinogenesis and explore the evidence on the safety of JAK inhibitors in relation to the risk of melanoma and non-melanoma skin cancer in patients with psoriasis and psoriatic arthritis.
Keywords
psoriatic arthritis, melanoma, skin cancer, psoriasis, JAK inhibitors
Coverage in
Integrated with
